Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BOLD-300
- Development stage
- Preclinical
- Lead developer
- Bold Therapeutics
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Intramuscular
01
Overview
BOLD-300 is an early-stage drug candidate being developed by Bold Therapeutics as part of its pipeline of metallotherapeutics. Bold Therapeutics focuses on the development of metal-based small molecules designed to treat advanced cancers that are resistant to standard therapies. While BOLD-300's specific molecular target and primary clinical indications have not been publicly disclosed in detail, it is part of a broader platform of ruthenium-based or other metal-based compounds that follow the company's lead candidate, BOLD-100 (a GRP78 inhibitor). The agent is being positioned within the company's oncology portfolio for the treatment of solid tumors.
02
Targets
HSPA5 (Heat shock protein family A member 5)RK (Ribokinase)
Beyond the preview
Go deeper on BOLD-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BOLD-300.